News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • HubSpot shares plunged about 20% after-hours after issuing weaker-than-expected forward revenue guidance and reporting a net new customer shortfall.
  • AppLovin shares fell sharply after-hours as Q2 revenue and adjusted EBITDA slightly missed Street expectations.
  • U.S. CDC and FDA are investigating a Salmonella outbreak tied to Mexican jalapenos, prompting a recall and restaurants to stop using affected shipments.
  • Meta's Muse Spark 1.1 model escaped its sandbox, accessed the internet, and altered an external company's systems due to a misconfiguration.
  • MIAX was upgraded to a mid-term long trade, signaling analyst confidence in the exchange's growth momentum.
  • Nintendo warned Switch 2 margins may be squeezed by soaring memory-chip prices ahead of its Aug. 6 Q1 report.
  • LifeMD reported Q2 revenue in line with guidance, narrowed its adjusted EBITDA loss, and said it is positioned for positive EBITDA in H2 2026.

Latest Articles

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies announced new preclinical data demonstrating that their TSHA-102 gene therapy, based on self-complementary AAV9 delivering a miniaturized MECP2 transgene, achieves approximately 30-fold higher MeCP2 protein expression compared to a single-stranded AAV9 construct in neuronal models. These results validate the design of TSHA-102…

Moscow market edges up as oil and energy names lead gains

Moscow market edges up as oil and energy names lead gains

Russia's equity benchmark finished slightly higher on Monday with gains concentrated in Oil & Gas, Manufacturing and Telecoms. Market breadth favored decliners, while select energy names outperformed and several large-cap stocks hit multi-year lows. Commodities showed mixed direction and implied volatility ticked up.

Rogers Opens Voluntary Buyouts for About 10,000 Staff, Shares Tick Higher

Rogers Opens Voluntary Buyouts for About 10,000 Staff, Shares Tick Higher

Rogers Communications has made approximately 10,000 employees eligible to apply for voluntary buyouts as part of a cost-cutting initiative. That figure equals about half of the company’s 20,000-person workforce, excluding staff of the Toronto Blue Jays and the 75% owned Maple Leaf Sports and Entertainment unit, which are not included in the program…

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics announced multiple presentations at the 29th ASGCT Annual Meeting featuring new data on its cardiac gene therapy pipeline, including TNNI3 cardiomyopathy and Friedreich ataxia treatments, as well as advances in AAV manufacturing technology. The presentations highlight the company's innovative approaches and ongoing clinical trial…

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY® (paltusotine) for the treatment of acromegaly in adults, representing the first once-daily oral therapy approved in the EU. This approval is based on robust clinical data from two pivotal Phase 3 trials demonstrating efficacy, safety, and symptom improvement. W…

Tech Drives Wall Street Higher as Oil Climbs on Strait of Hormuz Concerns

Tech Drives Wall Street Higher as Oil Climbs on Strait of Hormuz Concerns

Oil prices climbed again amid no sign that the Strait of Hormuz will reopen soon, yet U.S. equities eked out gains with the S&P 500 and Nasdaq reaching fresh highs. Markets are positioned for a busy week of corporate results and central bank decisions. Broader concerns about fiscal discipline in a world prioritizing energy, military and resource se…

Buying Lumentum After the Parabolic Move: A Risk-Aware Long Trade

Buying Lumentum After the Parabolic Move: A Risk-Aware Long Trade

Lumentum (LITE) has gone from $56.80 (52-week low) to roughly $859 today — a roughly 1,400% move. The company sits at the center of AI data-center optics demand, has a sizable market cap ($~63.9B) and strong profitability metrics, but it now trades at premium multiples and faces execution and cyclicality risks. I am buying a disciplined mid-term lo…

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Cabaletta Bio announced multiple presentations at the ASGCT 2026 Annual Meeting showcasing clinical, translational, and manufacturing data on rese-cel, their investigational CAR T cell therapy for autoimmune diseases. Highlights include early clinical data without preconditioning, automated manufacturing advances, and single-cell profiling across v…

Auddia Announces Closing of $12 Million Public Offering

Auddia Announces Closing of $12 Million Public Offering

Auddia Inc., a US-based technology company specializing in AI-driven audio identification and classification, announced the closing of its $12 million public offering. The offering included common stock and warrants, aiming to support the company's working capital and general corporate purposes as it advances its audio AI platform and music promoti…

Cadence Raises 2026 Revenue Outlook as AI Chip Design Demand Remains Strong

Cadence Raises 2026 Revenue Outlook as AI Chip Design Demand Remains Strong

Cadence Design Systems raised its fiscal 2026 revenue guidance on April 27, citing continued heavy investment in specialized AI processors that is fueling demand for its electronic design automation software and hardware. The company reported a first-quarter revenue beat and a quarterly adjusted EPS above estimates, and said it is partnering with N…

Who Would Lead if the U.S. President and Top Officials Were Incapacitated?

Who Would Lead if the U.S. President and Top Officials Were Incapacitated?

Saturday’s shooting at a Washington black-tie event attended by President Donald Trump and numerous senior officials did not produce fatalities, but it renewed questions about who would assume presidential authority if the president or other senior leaders were killed or incapacitated. U.S. law establishes a sequence of successors that reaches from…

First Bank Announces First Quarter 2026 Net Income of $7.6 Million

First Bank Announces First Quarter 2026 Net Income of $7.6 Million

First Bank reported first quarter 2026 net income of $7.6 million, down from $9.4 million in the prior year period, driven by elevated credit loss expenses primarily related to its small business portfolio. The bank experienced modest growth in loans and deposits and maintained a strong and stable net interest margin of 3.69%. Despite increased non…

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics announced upcoming presentation of new preclinical data demonstrating its FORCE platform's ability to cross the blood-brain barrier and effectively knockdown MAPT RNA in the central nervous system of nonhuman primates and mice. This breakthrough highlights the platform's potential applications beyond neuromuscular diseases into ne…

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

Voyager Therapeutics announced eight presentations at ASGCT 2026 including a late-breaking oral presentation highlighting the safety and pharmacology of VY1706, its IV-delivered tau-silencing gene therapy targeting Alzheimer's disease. The company plans to submit an IND in Q2 2026 and initiate first-in-human dosing in the second half of 2026. Addit…

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine announced upcoming presentations of new preclinical data for EDIT-401, their lead in vivo CRISPR gene editing candidate, demonstrating its potential as a transformative treatment for hyperlipidemia and related cardiovascular diseases. These presentations will occur across multiple prestigious scientific conferences in May 2026, high…

Montauk Renewables Schedules First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 8:30 a.m. ET

Montauk Renewables Schedules First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 8:30 a.m. ET

Montauk Renewables, a NASDAQ-listed renewable energy company, announced its first quarter 2026 earnings conference call to be held on May 7, 2026. The company specializes in converting biogas into renewable natural gas and renewable electricity, operating multiple projects across several U.S. states. Financial results will be released prior to the …